english.prescrire.org > Spotlight > 100 most recent > Abemaciclib (Verzenios°), palbociclib (Ibrance°) and ribociclib (Kisqali°) added to an aromatase inhibitor in certain breast cancers

Spotlight

Every month, the subjects in Prescrire’s Spotlight.

100 most recent :  1 | 10 | 20 | 30 | 40 | 50 | 60 | 70 | 80 | 90

Abemaciclib (Verzenios°), palbociclib (Ibrance°) and ribociclib (Kisqali°) added to an aromatase inhibitor in certain breast cancers

 Marketing Authorisations   Abemaciclib, palbociclib and ribociclib have been authorised since the late 2010s for use in postmenopausal women with locally advanced or metastatic breast cancer, whose tumour cells express hormone receptors but do not overexpress the HER2 protein. According to the initial clinical evaluation of each of these CDK 4/6 inhibitors ("ciclibs"), none of them extended survival, while an increased incidence of serious adverse effects was reported. With longer follow-up, does the addition of a CDK 4/6 inhibitor to an aromatase inhibitor extend survival? And what more is known about their adverse effects?
Full article (3 pages) available for download by subscribers

©Prescrire 1 January 2024

Source: "Abemaciclib (Verzenios°), palbociclib (Ibrance°) and ribociclib (Kisqali°) added to an aromatase inhibitor in certain breast cancers" Prescrire Int 2024; 33 (255): 5-7. Subscribers only.

Enjoy full access to Prescrire International, and support independent information